Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen

The Lancet Infectious Diseases

Volumn 17, Issue 4, 2017, Pages e107-e117

  Burt, Felicity J ^a   Chen, Weiqiang ^b   Miner, Jonathan J ^c   Lenschow, Deborah J ^c   Merits, Andres ^d   Schnettler, Esther ^e   Kohl, Alain ^f   Rudd, Penny A ^b   Taylor, Adam ^b   Herrero, Lara J ^b   Zaid, Ali ^b   Ng, Lisa F P ^g,h   Mahalingam, Suresh ^b  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b GRIFFITH UNIVERSITY   (Australia)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TARTU   (Estonia)

^e BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^f MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^g AGENCY FOR SCIENCE   (Singapore)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHIKUNGUNYA VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL MODEL; ANTIVIRAL THERAPY; CHEMICAL STRUCTURE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CLINICAL FEATURE; GENOME ANALYSIS; HUMAN; INFECTION CONTROL; MOLECULAR EVOLUTION; MOUSE MODEL; NONHUMAN; PRIMATE MODEL; PRIORITY JOURNAL; REVIEW; VIROLOGY; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; AEDES; ANIMAL; CHIKUNGUNYA FEVER; COMMUNICABLE DISEASE; EPIDEMIC; GENETICS; GLOBAL HEALTH; IMMUNOLOGY; INSECT VECTOR; ISOLATION AND PURIFICATION; PATHOGENICITY;

AEDES; ANIMALS; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; GLOBAL HEALTH; HUMANS; INSECT VECTORS; MODELS, ANIMAL;

EID: 85011064147     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30385-1     Document Type: Review

References (168)

1. 1 Robinson, MC, An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I. Clinical features. Trans R Soc Trop Med Hyg 49 (1955), 28–32.
2. 2 Suhrbier, A, Jaffar-Bandjee, M-C, Gasque, P, Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol 8 (2012), 420–429.
3. 3 Joubert, JJ, Prozesky, OW, Lourens, JG, et al. Prevalence of hepatitis virus and some arbovirus infections in Kavango, northern SWA/Namibia. S Afr Med J 67 (1985), 500–502.
4. 4 Josseran, L, Paquet, C, Zehgnoun, A, et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 12 (2006), 1994–1995.
5. 5 Rampal, SM, Meena, H, Neurological complications in chikungunya fever. J Assoc Physicians India 55 (2007), 765–769.
6. 6 Wielanek, AC, Monredon, JD, Amrani, ME, Roger, JC, Serveaux, JP, Guillain-barre syndrome complicating a chikungunya virus infection. Neurology 69 (2007), 2105–2107.
7. 7 Diallo, M, Thonnon, J, Traore-Lamizana, M, Fontenille, D, Vectors of chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg 60 (1999), 281–286.
8. 8 Tsetsarkin, KA, Vanlandingham, DL, McGee, CE, Higgs, S, A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog, 3, 2007, e201.
9. 9 Weaver, SC, Forrester, NL, Chikungunya: evolutionary history and recent epidemic spread. Antiviral Res 120 (2015), 32–39.
10. 10 Rezza, G, Nicoletti, L, Angelini, R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370 (2007), 1840–1846.
11. 11 Gould, EA, Gallian, P, De Lamballerie, X, Charrel, RN, First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality!. Clin Microbiol Infect 16 (2010), 1702–1704.
12. 12 Delisle, E, Rousseau, C, Broche, B, et al. Chikungunya outbreak in Montpellier, France, September to October 2014. Euro Surveill, 20, 2015, 21108.
13. 13 Cassadou, S, Boucau, S, Petit-Sinturel, M, Huc, P, Leparc-Goffart, I, Ledrans, M, Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. Euro Surveill, 19, 2014, 20752.
14. 14 Leparc-Goffart, I, Nougairede, A, Cassadou, S, Prat, C, de Lamballerie, X, Chikungunya in the Americas. Lancet, 383, 2014, 514.
15. 15 Van Bortel, W, Dorleans, F, Rosine, J, et al. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill, 19, 2014, 20759.
16. 16 Petersen, LR, Powers, AM, Chikungunya: epidemiology. F1000Research, 5, 2016, 82.
17. 17 Chen, R, Wang, E, Tsetsarkin, KA, Weaver, SC, Chikungunya virus 3′ untranslated region: adaptation to mosquitoes and a population bottleneck as major evolutionary forces. PLoS Pathog, 9, 2013, e1003591.
18. 18 Van Duijl-Richter, MKS, Hoornweg, TE, Rodenhuis-Zybert, IA, Smit, JM, Early events in chikungunya virus infection—from virus cell binding to membrane fusion. Viruses 7 (2015), 3647–3674.
19. 19 Utt, A, Das, PK, Varjak, M, Lulla, V, Lulla, A, Merits, A, Mutations conferring a noncytotoxic phenotype on chikungunya virus replicons compromise enzymatic properties of nonstructural protein 2. J Virol 89 (2015), 3145–3162.
20. 20 Karpe, YA, Aher, PP, Lole, KS, NTPase and 5′-RNA triphosphatase activities of chikungunya virus nsP2 protein. PLoS One, 6, 2011, e22336.
21. 21 Das, PK, Merits, A, Lulla, A, Functional cross-talk between distant domains of chikungunya virus non-structural protein 2 is decisive for its RNA-modulating activity. J Biol Chem 289 (2014), 5635–5653.
22. 22 Akhrymuk, I, Kulemzin, SV, Frolova, EI, Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J Virol 86 (2012), 7180–7191.
23. 23 Fros, JJ, Liu, WJ, Prow, NA, et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol 84 (2010), 10877–10887.
24. 24 Fros, JJ, van der Maten, E, Vlak, JM, Pijlman, GP, The C-terminal domain of chikungunya virus nsP2 independently governs viral RNA replication, cytopathicity, and inhibition of interferon signaling. J Virol 87 (2013), 10394–10400.
25. 25 Fros, JJ, Major, LD, Scholte, FEM, et al. Chikungunya virus non-structural protein 2-mediated host shut-off disables the unfolded protein response. J Gen Virol 96 (2015), 580–589.
26. 26 Judith, D, Mostowy, S, Bourai, M, et al. Species-specific impact of the autophagy machinery on chikungunya virus infection. EMBO Rep 14 (2013), 534–544.
27. 27 Malet, H, Coutard, B, Jamal, S, et al. The crystal structures of chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J Virol 83 (2009), 6534–6545.
28. 28 Panas, MD, Ahola, T, McInerney, GM, The C-terminal repeat domains of nsP3 from the Old World alphaviruses bind directly to G3BP. J Virol 88 (2014), 5888–5893.
29. 29 Neuvonen, M, Kazlauskas, A, Martikainen, M, Hinkkanen, A, Ahola, T, Saksela, K, SH3 domain-mediated recruitment of host cell amphiphysins by alphavirus nsP3 promotes viral RNA replication. PLoS Pathog, 7, 2011, e1002383.
30. 30 Bouraï, M, Lucas-Hourani, M, Gad, HH, et al. Mapping of chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol 86 (2012), 3121–3134.
31. 31 Treffers, EE, Tas, A, Scholte, FEM, et al. Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication. Proteomics 15 (2015), 2267–2280.
32. 32 Das, I, Basantray, I, Mamidi, P, et al. Heat shock protein 90 positively regulates chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. PLoS One, 9, 2014, e100531.
33. 33 Rathore, APS, Haystead, T, Das, PK, Merits, A, Ng, M-L, Vasudevan, SG, Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antiviral Res 103 (2014), 7–16.
34. 34 Dickson, AM, Anderson, JR, Barnhart, MD, et al. Dephosphorylation of HuR protein during alphavirus infection is associated with HuR relocalization to the cytoplasm. J Biol Chem 287 (2012), 36229–36238.
35. 35 Panas, MD, Varjak, M, Lulla, A, et al. Sequestration of G3BP coupled with efficient translation inhibits stress granules in Semliki Forest virus infection. Mol Biol Cell 23 (2012), 4701–4712.
36. 36 Scholte, FEM, Tas, A, Albulescu, IC, et al. Stress granule components G3BP1 and G3BP2 play a proviral role early in chikungunya virus replication. J Virol 89 (2015), 4457–4469.
37. 37 Rupp, JC, Sokoloski, KJ, Gebhart, NN, Hardy, RW, Alphavirus RNA synthesis and nonstructural protein functions. J Gen Virol 96 (2015), 2483–2500.
38. 38 Kim, DY, Firth, AE, Atasheva, S, Frolova, EI, Frolov, I, Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution. J Virol 85 (2011), 8022–8036.
39. 39 Scholte, FEM, Tas, A, Martina, BEE, et al. Characterization of synthetic chikungunya viruses based on the consensus sequence of recent E1-226V isolates. PLoS One, 8, 2013, e71047.
40. 40 Thomas, S, Rai, J, John, L, Schaefer, S, Pützer, BM, Herchenröder, O, Chikungunya virus capsid protein contains nuclear import and export signals. Virol J, 10, 2013, 269.
41. 41 Ooi, YS, Dubé, M, Kielian, M, BST2/tetherin inhibition of alphavirus exit. Viruses 7 (2015), 2147–2167.
42. 42 Jones, PH, Maric, M, Madison, MN, Maury, W, Roller, RJ, Okeoma, CM, BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 438 (2013), 37–49.
43. 43 Lim, PJ, Chu, JJH, A polarized cell model for chikungunya virus infection: entry and egress of virus occurs at the apical domain of polarized cells. PLoS Negl Trop Dis, 8, 2014, e2661.
44. 44 Filipe, AF, Pinto, MR, Arbovirus studies in Luanda, Angola. 2. Virological and serological studies during an outbreak of dengue-like disease caused by the Chikungunya virus. Bull World Health Organ 49 (1973), 37–40.
45. 45 Eisenhut, M, Schwarz, TF, Hegenscheid, B, Seroprevalence of dengue, chikungunya and Sindbis virus infections in German aid workers. Infection 27 (1999), 82–85.
46. 46 Rodhain, F, Carteron, B, Laroche, R, Hannoun, C, Human arbovirus infections in Burundi: results of a seroepidemiologic survey, 1980–1982. Bull Soc Pathol Exot Filiales 80 (1987), 155–161 (in French).
47. 47 Kuniholm, MH, Wolfe, ND, Huang, CY-H, et al. Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults. Am J Trop Med Hyg 74 (2006), 1078–1083.
48. 48 Peyrefitte, CN, Rousset, D, Pastorino, BAM, et al. Chikungunya virus, Cameroon, 2006. Emerg Infect Dis 13 (2007), 768–771.
49. 49 Guilherme JM, Gonella-Legall C, Legall F, Nakoume E, Vincent J. Seroprevalence of five arboviruses in Zebu cattle in the Central African Republic. Trans R Soc Trop Med Hyg; 90: 31–3.
50. 50 Pastorino, B, Muyembe-Tamfum, JJ, Bessaud, M, et al. Epidemic resurgence of chikungunya virus in democratic Republic of the Congo: identification of a new central African strain. J Med Virol 74 (2004), 277–282.
51. 51 Peyrefitte, CN, Bessaud, M, Pastorino, BAM, et al. Circulation of chikungunya virus in Gabon, 2006–2007. J Med Virol 80 (2008), 430–433.
52. 52 Jentes, ES, Robinson, J, Johnson, BW, et al. Acute arboviral infections in Guinea, West Africa, 2006. Am J Trop Med Hyg 83 (2010), 388–394.
53. 53 Sergon, K, Njuguna, C, Kalani, R, et al. Seroprevalence of chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg 78 (2008), 333–337.
54. 54 Kaschula, VR, Van Dellen, AF, de Vos, V, Some infectious diseases of wild vervet monkeys (Cercopithecus aethiops pygerythrus) in South Africa. J S Afr Vet Assoc 49 (1978), 223–237.
55. 55 Pistone, T, Ezzedine, K, Schuffenecker, I, Receveur, M-C, Malvy, D, An imported case of chikungunya fever from Madagascar: use of the sentinel traveller for detecting emerging arboviral infections in tropical and European countries. Travel Med Infect Dis 7 (2009), 52–54.
56. 56 Van den Bosch, C, Lloyd, G, Chikungunya fever as a risk factor for endemic Burkitt's lymphoma in Malawi. Trans R Soc Trop Med Hyg 94 (2000), 704–705.
57. 57 Moore, DL, Causey, OR, Carey, DE, et al. Arthropod-borne viral infections of man in Nigeria, 1964–1970. Ann Trop Med Parasitol 69 (1975), 49–64.
58. 58 Weinbren, MP, Haddow, AJ, Williams, MC, The occurrence of Chikungunya virus in Uganda. I. Isolation from mosquitoes. Trans R Soc Trop Med Hyg 52 (1958), 253–257.
59. 59 Pistone, T, Ezzedine, K, Boisvert, M, et al. Cluster of chikungunya virus infection in travelers returning from Senegal. J Travel Med 16 (2006), 286–288.
60. 60 Woodruff, AW, Bowen, ET, Platt, GS, Viral infections in travellers from tropical Africa. BMJ 1 (1978), 956–958.
61. 61 Gould, LH, Osman, MS, Farnon, EC, et al. An outbreak of yellow fever with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005. Trans R Soc Trop Med Hyg 102 (2008), 1247–1254.
62. 62 Lahariya, C, Pradhan, SK, Emergence of chikungunya virus in Indian subcontinent after 32 years: a review. J Vector Borne Dis 43 (2006), 151–160.
63. 63 Rao, TR, Immunological surveys of arbovirus infections in South-East Asia, with special reference to dengue, chikungunya, and Kyasanur Forest disease. Bull World Health Organ 44 (1971), 585–591.
64. 64 Mackenzie, JS, Chua, KB, Daniels, PW, et al. Emerging viral diseases of Southeast Asia and the Western Pacific. Emerg Infect Dis 7 (2001), 497–504.
65. 65 Sarkar, JK, Pavri, KM, Chatterjee, SN, Chakravarty, SK, Anderson, CR, Virological and serological studies of cases of haemorrhagice fever in Calcutta. Material collected by the Calcutta School of Tropical Medicine. Indian J Med Res 52 (1964), 684–691.
66. 66 Wangchuk, S, Chinnawirotpisan, P, Dorji, T, et al. Chikungunya fever outbreak, Bhutan, 2012. Emerg Infect Dis 19 (2013), 1681–1684.
67. 67 Hussain, R, Alomar, I, Memish, ZA, Chikungunya virus: emergence of an arthritic arbovirus in Jeddah, Saudi Arabia. East Mediterr Health J 19 (2013), 506–508.
68. 68 Rezza, G, El-Sawaf, G, Faggioni, G, et al. Co-circulation of dengue and chikungunya viruses, Al Hudaydah, Yemen, 2012. Emerg Infect Dis 20 (2014), 1351–1354.
69. 69 Powers, AM, Brault, AC, Tesh, RB, Weaver, SC, Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol 81 (2000), 471–479.
70. 70 Schuffenecker, I, Iteman, I, Michault, A, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med, 3, 2006, e263.
71. 71 Laras, K, Sukri, NC, Larasati, RP, et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 99 (2005), 128–141.
72. 72 Sergon, K, Yahaya, AA, Brown, J, et al. Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg 76 (2007), 1189–1193.
73. 73 Pialoux, G, Gaüzère, B-A, Jauréguiberry, S, Strobel, M, Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 7 (2007), 319–327.
74. 74 Renault, P, Solet, J-L, Sissoko, D, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005–2006. Am J Trop Med Hyg 77 (2007), 727–731.
75. 75 D'Ortenzio, E, Grandadam, M, Balleydier, E, et al. Sporadic cases of chikungunya, Réunion Island, August 2009. Euro Surveill, 14, 2009, 19324.
76. 76 D'Ortenzio, E, Grandadam, M, Balleydier, E, et al. A226V strains of chikungunya virus, Réunion Island, 2010. Emerg Infect Dis 17 (2011), 309–311.
77. 77 Arankalle, VA, Shrivastava, S, Cherian, S, et al. Genetic divergence of chikungunya viruses in India (1963–2006) with special reference to the 2005–2006 explosive epidemic. J Gen Virol 88 (2007), 1967–1976.
78. 78 Mourya, DT, Thakare, JR, Gokhale, MD, et al. Isolation of chikungunya virus from Aedes aegypti mosquitoes collected in the town of Yawat, Pune District, Maharashtra State, India. Acta Virol 45 (2001), 305–309.
79. 79 Vazeille, M, Moutailler, S, Coudrier, D, et al. Two chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS One, 2, 2007, e1168.
80. 80 Tsetsarkin, KA, Weaver, SC, Sequential adaptive mutations enhance efficient vector switching by chikungunya virus and its epidemic emergence. PLoS Pathog, 7, 2011, e1002412.
81. 81 Tsetsarkin, KA, Chen, R, Leal, G, et al. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci USA 108 (2011), 7872–7877.
82. 82 Lanciotti, RS, Valadere, AM, Transcontinental movement of Asian genotype chikungunya virus. Emerg Infect Dis 20 (2014), 1400–1402.
83. 83 Nunes, MRT, Faria, NR, de Vasconcelos, JM, et al. Emergence and potential for spread of chikungunya virus in Brazil. BMC Med, 13, 2015, 102.
84. 84 Sy, AK, Saito-Obata, M, Medado, IA, et al. Molecular characterization of chikungunya virus, Philippines, 2011–2013. Emerg Infect Dis 22 (2016), 887–890.
85. 85 Merkling, SH, van Rij, RP, Beyond RNAi: antiviral defense strategies in Drosophila and mosquito. J Insect Physiol 59 (2013), 159–170.
86. 86 McFarlane, M, Arias-Goeta, C, Martin, E, et al. Characterization of Aedes aegypti innate-immune pathways that limit Chikungunya virus replication. PLoS Negl Trop Dis, 8, 2014, e2994.
87. 87 Donald, CL, Kohl, A, Schnettler, E, New insights into control of arbovirus replication and spread by insect RNA interference pathways. Insects 3 (2012), 511–531.
88. 88 Morazzani, EM, Wiley, MR, Murreddu, MG, Adelman, ZN, Myles, KM, Production of virus-derived ping-pong-dependent piRNA-like small RNAs in the mosquito soma. PLoS Pathog, 8, 2012, e1002470.
89. 89 Bartel, DP, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
90. 90 Shrinet, J, Jain, S, Jain, J, Bhatnagar, RK, Sunil, S, Next generation sequencing reveals regulation of distinct Aedes microRNAs during chikungunya virus development. PLoS Negl Trop Dis, 8, 2014, e2616.
91. 91 Maharaj, PD, Widen, SG, Huang, J, Wood, TG, Thangamani, S, Discovery of mosquito saliva microRNAs during CHIKV infection. PLoS Negl Trop Dis, 9, 2015, e0003386.
92. 92 Miner, JJ, Aw Yeang, HX, Fox, JM, et al. Brief report: chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. Arthritis Rheumatol 67 (2015), 1214–1220.
93. 93 Mahendradas, P, Avadhani, K, Shetty, R, Chikungunya and the eye: a review. J Ophthalmic Inflamm Infect, 3, 2013, 35.
94. 94 Mohan, A, Kiran, DHN, Manohar, IC, Kumar, DP, Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic. Indian J Dermatol 55 (2010), 54–63.
95. 95 Simon, F, Javelle, E, Oliver, M, Leparc-Goffart, I, Marimoutou, C, Chikungunya virus infection. Curr Infect Dis Rep 13 (2011), 218–228.
96. 96 Borgherini, G, Poubeau, P, Staikowsky, F, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis 44 (2007), 1401–1407.
97. 97 Brighton, SW, Prozesky, OW, de la Harpe, AL, Chikungunya virus infection. A retrospective study of 107 cases. S Afr Med J 63 (1983), 313–315.
98. 98 Hochedez, P, Jaureguiberry, S, Debruyne, M, et al. Chikungunya infection in travelers. Emerg Infect Dis 12 (2006), 1565–1567.
99. 99 Marimoutou, C, Vivier, E, Oliver, M, Boutin, J-P, Simon, F, Morbidity and impaired quality of life 30 months after chikungunya infection: comparative cohort of infected and uninfected French military policemen in Reunion Island. Medicine 91 (2012), 212–219.
100. 100 Schilte, C, Staikowsky, F, Staikovsky, F, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis, 7, 2013, e2137.
101. 101 Rajapakse, S, Rodrigo, C, Rajapakse, A, Atypical manifestations of chikungunya infection. Trans R Soc Trop Med Hyg 104 (2010), 89–96.
102. 102 Singh, SS, Manimunda, SP, Sugunan, AP, Sahina, Vijayachari, P, Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect 136 (2008), 1277–1280.
103. 103 Lemant, J, Boisson, V, Winer, A, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005–2006. Crit Care Med 36 (2008), 2536–2541.
104. 104 Ramful, D, Carbonnier, M, Pasquet, M, et al. Mother-to-child transmission of chikungunya virus infection. Pediatr Infect Dis J 26 (2007), 811–815.
105. 105 Gérardin, P, Sampériz, S, Ramful, D, et al. Neurocognitive outcome of children exposed to perinatal mother-to-child chikungunya virus infection: the CHIMERE cohort study on Reunion Island. PLoS Negl Trop Dis, 8, 2014, e2996.
106. 106 Brighton, SW, Simson, IW, A destructive arthropathy following chikungunya virus arthritis—a possible association. Clin Rheumatol 3 (1984), 253–258.
107. 107 Malvy, D, Ezzedine, K, Mamani-Matsuda, M, et al. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis, 9, 2009, 200.
108. 108 Manimunda, SP, Vijayachari, P, Uppoor, R, et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg 104 (2010), 392–399.
109. 109 Chirathaworn, C, Poovorawan, Y, Lertmaharit, S, Wuttirattanakowit, N, Cytokine levels in patients with chikungunya virus infection. Asian Pac J Trop Med 6 (2013), 631–634.
110. 110 Kelvin, AA, Banner, D, Silvi, G, et al. Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis, 5, 2011, e1279.
111. 111 Reddy, V, Mani, RS, Desai, A, Ravi, V, Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute chikungunya virus infection. J Med Virol 86 (2014), 1393–1401.
112. 112 Teng, T-S, Kam, Y-W, Lee, B, et al. A systematic meta-analysis of immune signatures in patients with acute chikungunya virus infection. J Infect Dis 211 (2015), 1925–1935.
113. 113 Teo, T-H, Lum, F-M, Claser, C, et al. A pathogenic role for CD4+ T cells during chikungunya virus infection in mice. J Immunol 190 (2013), 259–269.
114. 114 Seymour, RL, Adams, AP, Leal, G, Alcorn, MDH, Weaver, SC, A rodent model of chikungunya virus infection in RAG1 -/- mice, with features of persistence, for vaccine safety evaluation. PLoS Negl Trop Dis, 9, 2015, e0003800.
115. 115 Kam, Y-W, Lee, WWL, Simarmata, D, et al. Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 86 (2012), 13005–13015.
116. 116 Smith, SA, Silva, LA, Fox, JM, et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18 (2015), 86–95.
117. 117 Noret, M, Herrero, L, Rulli, N, et al. Interleukin 6, RANKL, and osteoprotegerin expression by chikungunya virus-infected human osteoblasts. J Infect Dis 206 (2012), 455–457 457–59.
118. 118 Labadie, K, Larcher, T, Joubert, C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120 (2010), 894–906.
119. 119 Binn, LN, Harrison, VR, Randall, R, Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg 16 (1967), 782–785.
120. 120 Paul, SD, Singh, KR, Experimental infection of Macaca radiata with chikungunya virus and transmission of virus by mosquitoes. Indian J Med Res 56 (1968), 802–811.
121. 121 Chen, C-I, Clark, DC, Pesavento, P, et al. Comparative pathogenesis of epidemic and enzootic chikungunya viruses in a pregnant Rhesus macaque model. Am J Trop Med Hyg 83 (2010), 1249–1258.
122. 122 Messaoudi, I, Vomaske, J, Totonchy, T, et al. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis, 7, 2013, e2343.
123. 123 Her, Z, Teng, T-S, Tan, JJL, et al. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. EMBO Mol Med 7 (2015), 24–41.
124. 124 Chen, W, Foo, S-S, Taylor, A, et al. Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection. J Virol 89 (2015), 581–593.
125. 125 Poo, YS, Nakaya, H, Gardner, J, et al. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis. J Virol 88 (2014), 6862–6872.
126. 126 Herrero, LJ, Sheng, K-C, Jian, P, et al. Macrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infection. Arthritis Rheum 65 (2013), 2724–2736.
127. 127 Rudd, PA, Wilson, J, Gardner, J, et al. Interferon response factors 3 and 7 protect against chikungunya virus hemorrhagic fever and shock. J Virol 86 (2012), 9888–9898.
128. 128 White, LK, Sali, T, Alvarado, D, et al. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. J Virol 85 (2011), 606–620.
129. 129 Nakaya, HI, Gardner, J, Poo, Y-S, Major, L, Pulendran, B, Suhrbier, A, Gene profiling of chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum 64 (2012), 3553–3563.
130. 130 Hawman, DW, Stoermer, KA, Montgomery, SA, et al. Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response. J Virol 87 (2013), 13878–13888.
131. 131 De Lamballerie, X, Ninove, L, Charrel, RN, Antiviral treatment of chikungunya virus infection. Infect Disord Drug Targets 9 (2009), 101–104.
132. 132 Briolant, S, Garin, D, Scaramozzino, N, Jouan, A, Crance, JM, In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 61 (2004), 111–117.
133. 133 Khan, M, Dhanwani, R, Patro, IK, Rao, PVL, Parida, MM, Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 89 (2011), 1–8.
134. 134 Kaur, P, Chu, JJH, Chikungunya virus: an update on antiviral development and challenges. Drug Discov Today 18 (2013), 969–983.
135. 135 Delang, L, Segura Guerrero, N, Tas, A, et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69 (2014), 2770–2784.
136. 136 Bassetto, M, De Burghgraeve, T, Delang, L, et al. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Res 98 (2013), 12–18.
137. 137 Allard, P-M, Leyssen, P, Martin, M-T, et al. Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri. Phytochemistry 84 (2012), 160–168.
138. 138 Bourjot, M, Delang, L, Nguyen, VH, et al. Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of chikungunya virus replication. J Nat Prod 75 (2012), 2183–2187.
139. 139 Pohjala, L, Alakurtti, S, Ahola, T, Yli-Kauhaluoma, J, Tammela, P, Betulin-derived compounds as inhibitors of alphavirus replication. J Nat Prod 72 (2009), 1917–1926.
140. 140 Cruz, DJM, Bonotto, RM, Gomes, RGB, et al. Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis, 7, 2013, e2471.
141. 141 Harrison, VR, Eckels, KH, Bartelloni, PJ, Hampton, C, Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 107 (1971), 643–647.
142. 142 DeMeio, JL, DeSanctis, AN, Thomas, WJ, Persistence in humans of antibody after immunization with four alphavirus vaccines. Asian J Infect Dis 3 (1979), 119–124.
143. 143 Levitt, NH, Ramsburg, HH, Hasty, SE, Repik, PM, Cole, FE, Lupton, HW, Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4 (1986), 157–162.
144. 144 Hoke, CH, Pace-Templeton, J, Pittman, P, et al. US Military contributions to the global response to pandemic chikungunya. Vaccine 30 (2012), 6713–6720.
145. 145 Chu, H, Das, SC, Fuchs, JF, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against chikungunya in the A129 mouse model. Vaccine 31 (2013), 3353–3360.
146. 146 Plante, K, Wang, E, Partidos, CD, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog, 7, 2011, e1002142.
147. 147 Partidos, CD, Paykel, J, Weger, J, et al. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30 (2012), 4638–4643.
148. 148 Roy, CJ, Adams, AP, Wang, E, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 209 (2014), 1891–1899.
149. 149 Hallengärd, D, Kakoulidou, M, Lulla, A, et al. Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol 88 (2014), 2858–2866.
150. 150 Akahata, W, Yang, Z-Y, Andersen, H, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 16 (2010), 334–338.
151. 151 Metz, SW, Pijlman, GP, Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. J Invertebr Pathol 107:suppl (2011), 16–30.
152. 152 Metz, SW, Martina, BE, van den Doel, P, et al. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 31 (2013), 6092–6096.
153. 153 Akahata, W, Nabel, GJ, A specific domain of the chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J Virol 86 (2012), 8879–8883.
154. 154 Brandler, S, Ruffié, C, Combredet, C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31 (2013), 3718–3725.
155. 155 Chang, L-J, Dowd, KA, Mendoza, FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384 (2014), 2046–2052.
156. 156 Ramsauer, K, Schwameis, M, Firbas, C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15 (2015), 519–527.
157. 157 Wang, D, Suhrbier, A, Penn-Nicholson, A, et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29 (2011), 2803–2809.
158. 158 Chattopadhyay, A, Wang, E, Seymour, R, Weaver, SC, Rose, JK, A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol 87 (2013), 395–402.
159. 159 García-Arriaza, J, Cepeda, V, Hallengärd, D, et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 88 (2014), 3527–3547.
160. 160 Muthumani, K, Lankaraman, KM, Laddy, DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 26 (2008), 5128–5134.
161. 161 Mallilankaraman, K, Shedlock, DJ, Bao, H, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis, 5, 2011, e928.
162. 162 Bao, H, Ramanathan, AA, Kawalakar, O, et al. Nonstructural protein 2 (nsP2) of chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA vaccine. Viral Immunol 26 (2013), 75–83.
163. 163 Khan, M, Dhanwani, R, Rao, PVL, Parida, M, Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res 167 (2012), 236–246.
164. 164 Kumar, M, Sudeep, AB, Arankalle, VA, Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30 (2012), 6142–6149.
165. 165 Couderc, T, Khandoudi, N, Grandadam, M, et al. Prophylaxis and therapy for chikungunya virus infection. J Infect Dis 200 (2009), 516–523.
166. 166 Fric, J, Bertin-Maghit, S, Wang, C-I, Nardin, A, Warter, L, Use of human monoclonal antibodies to treat chikungunya virus infection. J Infect Dis 207 (2013), 319–322.
167. 167 Selvarajah, S, Sexton, NR, Kahle, KM, et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis, 7, 2013, e2423.
168. 168 Fox, JM, Long, F, Edeling, MA, et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163 (2015), 1095–1107.